We can’t show the full text here under this license.
Using multiple gene edits to create off-the-shelf CAR T-cells targeting EGFR for better treatment of solid tumors
Updated
Abstract
A combination of six gene edits in T-cells may enhance their effectiveness against solid tumors.
- Chimeric Antigen Receptor (CAR) T-cells have shown strong responses in blood cancers but struggle with solid tumors due to immunosuppressive barriers.
- The engineered CAR T-cells are designed to resist both biochemical and immunological signaling that inhibits their activity in solid tumors.
- Gene edits targeting pathways related to allorejection, graft-versus-host disease, and tumor microenvironment barriers were successfully implemented.
- This approach demonstrated improved anti-tumor efficacy and survival in mouse models with human lung tumors.
- The strategy may offer a new way to enhance CAR T-cell therapy's potential against solid tumors.
Simplified
Key numbers
67%
Tumor-free Mice Proportion
Proportion of mice treated with TKO T-cells that achieved tumor elimination.
2×
Tumor Volume Reduction
Ratio of TKO T-cell infiltration in tumors compared to control T-cells.